Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

F-Prime Capital

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 467
Average round size
info
The average size of a deal this fund participated in
$44M
Portfolio companies 257
Rounds per year 5.99
Lead investments 27
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.45
Exits 63
Key employees 11
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Software
  • Therapeutics

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of F-Prime Capital:
Typical Co-investors
F-Prime Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after F-Prime Capital:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

AvenCell

Health Care
22 Oct 2024 Cambridge, Massachusetts, United States

Shift Bioscience

Biopharma
Biotechnology
Machine Learning
Pharmaceutical
15 Oct 2024 Cambridge, Cambridgeshire, United Kingdom

Spry

Fitness
Health Care
Wellness
09 Oct 2024 New Jersey, Maryland, United States

Rippl Care

Health Care
02 Oct 2024 Seattle, Washington, United States

Canoe

Analytics
Artificial Intelligence
FinTech
Information Technology
Machine Learning
Robotics
SaaS
Software
$36M09 Jul 2024 New York, New York, United States

Odaseva

Big Data
Business Information Systems
Cloud Security
Compliance
Enterprise Software
Information Technology
SaaS
Software
$54M27 Jun 2024 San Francisco, California, United States

Canary Technologies

Enterprise Software
Hospitality
Hotel
Software
$50M12 Jun 2024 San Francisco, California, United States

Amber Therapeutics

Biotechnology
Therapeutics
$109M10 Jun 2024 London, England, United Kingdom

Quantum Circuits

Computer
Manufacturing
Quantum Computing
Software
$60M31 May 2024 New Haven, Connecticut, United States
News
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Centivo raises $51 million as more employers seek affordable, quality healthcare for their employees

– Centivo, a new health plan for self-funded employers that is anchored around leading providers of value-based care, announced today that it has raised an additional $51 million in funding.
B Capital Group, a leading global technology investor, and Maverick co-led the round.
– Additional existing investors, including Bain Capital Ventures, Company Ventures, Define Ventures, F-Prime Capital, HarbourVest Partners, Ingleside Investors, Nassau Street Ventures, an AVG fund and various individuals also participated.
– These funds will support Centivo’s rapid growth and expansion amid increased demand from employers for health plans that are structurally built to address employee healthcare affordability.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent F-Prime Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 467
Average round size 44M
Rounds per year 5.99
Peak activity year 2021
Lead investments 27
Follow on index 0.45
Exits 63
Group Appearance index 0.94

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

AvenCell

Health Care
22 Oct 2024 Cambridge, Massachusetts, United States

Shift Bioscience

Biopharma
Biotechnology
Machine Learning
Pharmaceutical
15 Oct 2024 Cambridge, Cambridgeshire, United Kingdom

Spry

Fitness
Health Care
Wellness
09 Oct 2024 New Jersey, Maryland, United States

Rippl Care

Health Care
02 Oct 2024 Seattle, Washington, United States

Canoe

Analytics
Artificial Intelligence
FinTech
Information Technology
Machine Learning
Robotics
SaaS
Software
$36M09 Jul 2024 New York, New York, United States

Odaseva

Big Data
Business Information Systems
Cloud Security
Compliance
Enterprise Software
Information Technology
SaaS
Software
$54M27 Jun 2024 San Francisco, California, United States

Canary Technologies

Enterprise Software
Hospitality
Hotel
Software
$50M12 Jun 2024 San Francisco, California, United States

Amber Therapeutics

Biotechnology
Therapeutics
$109M10 Jun 2024 London, England, United Kingdom

Quantum Circuits

Computer
Manufacturing
Quantum Computing
Software
$60M31 May 2024 New Haven, Connecticut, United States
Crunchbase icon

Content report

The following text will be sent to our editors: